Auteur/autrice : jberthold

DIVA EXPERTISE

by jbertholdin Institutions, Service Providers & others

DIVA EXPERTISE

About the company

DIVA Expertise offers an integrated service offering combining advice, studies and research and an innovative concept of “Turnkey R&D Project” whose general objective is to provide manufacturers with solutions and optimizations to their budget, deadline and production issues. Thanks to its expertise in adipose tissue, DIVA. Expertise supports manufacturers in identifying new action targets for their products and in developing a new scientific argument to help them differentiate themselves from existing competition.

About the solution

DIVA Expertise is a Contract Research Company (CRO) organized, to date, around five activities:


1) DIVA Conseils & Expertise: Scientific advice and expertise to support manufacturers in the management and coordination of research projects and in the valorization of the results of their research through the writing of scientific publications in international journals. reading committee.


2) DIVA Tests & Studies: carrying out preclinical tests and studies using innovative and scientifically validated human adipocyte models to provide the first scientific evidence of the effectiveness of an active ingredient or a finished product and to characterize its effects biological and its mode of action.


3) DIVA R&D: the company carries out internal research activity to develop study models that are ever closer to living things and adapted to the needs of manufacturers.


4) DIVA Biological Resources: the preparation and provision of biological resources to industrial or academic research teams.


5) DIVA Analyzes: analyzes of adipose tissue taken directly from volunteer or sick subjects participating in clinical research protocols.

Website
Key information

–  Therapeutic areas: Cosmetic, Nutraceutical

–  Based in: Toulouse (FRANCE)

–  Employees: 1 – 10

–  Created in: 2016

VECT-HORUS

by jbertholdin Biotech, Pharma

VECT-HORUS

About the company

Vect-Horus is a privately held biotechnology company that designs and develops molecular vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Founded in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), formerly headed by Dr Michel Khrestchatisky, co-founder of the company. Vect-Horus has 40 employees (most in R&D).

By combining pharmaceutical agents to its vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules (Oligonucleotides, Antibodies, NPs…).

Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, the Company is also targeting cancers (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need.

About the solution

VECT-HORUS discovered, validated, and optimized different families of molecular vector that target the LDL Receptor, Transferrin Receptor and undisclosed ones that allow drug targeted delivery to different organs.

The vectors are protected by several families of patents and ongoing patent applications. They have different properties (structure, affinity, stability, organ specificity) allowing adaptation of the vectorization process on a case-to-case basis.

Vect-Horus seeks to develop the broad potential of its proprietary VECTrans® technology platform through partnerships and licensing agreements with pharmaceutical and biotechnology companies in multiple therapeutic applications.

Website
Key information

–  Therapeutic areas: Central Nervous System, Neuromuscular, Cardiovascular, Ophtalmological, Oncology, Pulmonary

–  Based in: Marseille (FRANCE)

–  Employees: 11 – 50

–  Created in: 2005

INOVARION

by jbertholdin Institutions, Service Providers & others

INOVARION

About the company

Inovarion is a Life Sciences company based in Paris offering preclinical and fundamental research services.

Since 2013, Inovarion provides support to the pharmaceutical, biotechnology industries and academics in the form of research services outsourced on a contract basis. They help biotech companies to reach clinical trials faster outsourcing their R&D to Inovarion in France.

They have been working as an extension of their partners’ teams for Sanofi, L’Oréal, Inserm (French NIH), Gustave Roussy, and many more.

About the solution

Inovarion has developed a strong expertise in bioinformatics, oncology, immunology and molecular biology.
They are well established in the research landscape in France and published +140 scientific papers in the highest ranked reviews (Nature, Science, The Lancet, Cell…).

Here are their main advantages:
⁃ Scientific French excellence
⁃ Cost effectiveness thanks to French tax credits : 25%-40% less vs US project cost
⁃ Talent loyalty & stability: less than 5% staff turnover per year in our team

Their goal is to build up close and long-term cooperation with pharmaceutical and biotechnologiy companies worldwide, to offer them in France, very attractive conditions, both financial and time-saving, for conducting top-notch fundamental and preclinical research and beyond that, to achieve together scientifical victories in medicine.

Website
Key information

–  Therapeutic areas: Immuno-oncology, Neuroscience, Dermatology, Oncology, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 51-200

–  Created in: 2013

ARIANA PHARMACEUTICALS

by jbertholdin Digital Health

ARIANA PHARMACEUTICALS

About the company

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

About the solution

Ariana Pharma has developed an explainable artificial intelligence platform which explores all possible biomarker associations, generating results that can be used directly to design clinical trials and accelerate drug development. Based on the mathematical theories of Formal Concept Analysis and Gallois lattices, the power of the KEM® platform lies in its ability to deliver explainable results from small cohorts. KEM® is also effective at managing contradictions and heterogeneous data, ensuring the identification of relevant and accurate hypotheses that meet the needs of precision medicine.

Website
Key information

–  Therapeutic areas: Oncology, CNS, Cardiometabolic, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 11-50

–  Created in: 2003

MABQI

by jbertholdin Biotech, Pharma

MABQI

About the company

Mabqi is a high-tech developer of human therapeutic antibodies. Its phage display core technology platform allows the development of functional antibodies (including pH-sensitive antibodies selected from our oncology-dedicated library) with high developability through proprietary synthetic human libraries. Based on the technical expertise built on more than 20 successful discovery programs (Servier, ADC Therapeutics, … ) and the clinical expertise of its Medical Advisory Board, Mabqi is actively building a portfolio of first-in-class and best-in-class proprietary antibodies with high therapeutic potential in oncology.

Some of these assets are already available for partnered development and licensing opportunities. Mabqi provides also customized discovery services, including full antibody characterization, and has developed a unique and dedicated library to select pH-dependent antibodies for oncology indications.

About the solution

Thanks to smooth integration of high throughput discovery processes and AI, Mabqi is able to propose a portfolio of outstanding, readily developable antibodies: Tumor Microenvironment Targeting through pH sensitivity, excellent affinity ranges on membrane proteins and biological functionality are combined to offer solutions even in the most complicated cases.

Website
Key information

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Montpellier (FRANCE)

–  Employees: 11-50

–  Created in: 2017

ORAKL ONCOLOGY

by jbertholdin Biotech, Digital Health, Pharma

ORAKL ONCOLOGY

About the company

The current drug development process does not capture cancer complexity or heterogeneity. This is a main reason why 96% of drugs fail when they meet patients in clinical trials, lacking efficacy in the patient population.

Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development in collaboration with oncology players.


As a spin-out from Gustave Roussy (2023), the 4th cancer center in the world, Orakl’s boasts unique access to a vast repository of patient tissue samples and associated data. This strategic foundation positions them to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers.

The founders and team collectively bring unparalleled expertise in cancer cell biology and engineering. With over 30 years of combined academic experience across France, the UK, and the US, they are dedicated to improving cancer treatment. The company has already been funded 5M€ in equity and grants for their first developments.

About the solution

Orakl Oncology is a techbio platform that is building a unique collection of patient tumor avatars, each of them combining the best biology and patient clinical and molecular data. As a spin-out from Gustave Roussy, the 4th cancer center in the world, they are positionned to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers. This combination of biology and data, scalable and supported by proprietary know-how, is an extraordinary differenciating factor.


Their cutting-edge approach involves the integration of functional testing and AI-powered analysis to predict patient response to treatments and stratify populations. They already obtained excellent predictive values, at the patient and population levels.


Orakl discovers and develops new drugs that will succeed in the clinic, for their own pipeline or in co-development with oncology companies.

Website
Key information

–  Therapeutic areas: Oncology

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2023

CARTHERA

by jbertholdin Medtech

CARTHERA

About the company

Carthera is a clinical-stage company developing the SonoCloud, a revolutionary system to temporarily open the blood-brain barrier (BBB), and to improve CNS bioavailability of small molecules, ASOs, mAbs and other therapeutics. By using SonoCloud, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases.

About the solution

SonoCloud is an intracranial implant using low-intensity pulsed ultrasound (LIPU) to temporarily open the blood-brain barrier BBB before or after the injection of therapeutics. This innovative approach is being tested in several clinical programs in Glioblastoma with different chemotherapeutic agents as well as PDL-1 & CTLA-4 antibodies. SonoCloud is now entering the neurodegeneration field with focus on ALS, Huntington Disease and Parkinson Disease.

Website
Key information

–  Therapeutic areas: Oncology, Neurodegenerative diseases

–  Based in: Lyon (FRANCE) Office in Boston (USA)

–  Employees: 11 – 50

–  Created in: 2010

INFLECTIS BIOSCIENCE

by jbertholdin Biotech, Pharma

INFLECTIS BIOSCIENCE

About the company

InFlectis is a French-based drug discovery company, incoporated in 2013, developing first-in-class therapies for neurological rare diseases. They are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS. They are also ready to enter in phase 2 clinical trial in Charcot-Marie-Tooth disease and preclinical proof of efficacy has been obtained in rare cerebellar ataxias.

About the solution

IFB-088 is a first-in-class orally available small molecule drug candidate with a validated mechanism of action and a promising pharmacokinetic profile capable of crossing the blood brain barrier to target the central and peripheral nervous system. IFB-088 is a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR. The potential of IFB-088 lies in its ability to target different major cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.

Website
Key information

–  Therapeutic areas: Neurological rare diseases

–  Based in: Nantes (FRANCE)

–  Employees: 1-10

–  Created in: 2013

MABSILICO

by jbertholdin Biotech, Pharma

MABSILICO

About the company

MAbSilico is the TechBio pionner company specializing in computational solutions for discovering and designing therapeutic antibodies. Their solutions leverages artificial intelligence (AI) and machine learning to characterize, optimize and design therapeutic antibodies.

MAbSilico’s platform aims to accelerate the antibody discovery process by structural design with epitope-driven and multiparametric approaches. This allows to design highly effective antibodies, saving time and resources compared to traditional methods. We provide fully characterized antibodies against a target within 21 days that are internally validated with wet lab assays, leading to faster development of life-saving antibody therapies.

About the solution

MAbSilico uses a combination of 3D modeling, interaction simulation, and sequence analysis to identify promising antibody candidates after assessing for various factors, including their binding target (epitope), affinity, potential off-target effects, and developability.

While the solutions can be applied to antibody characterization, optimization and design, MAbSilico does not need to generate biological data to apply their solutions.

Integrating multi-parameters for the antibody design and validating the newly sequence with state of the art biological assays, MAbSilico is pioneering a game-changing approach to antibody discovery with internal discovery pipeline.

Website
Key information

–  Therapeutic areas: Computational antibody design & discovery applied in oncology, Immuno-oncology, Infectious diseases, Rare diseases

–  Based in: Tours & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2017

4P-PHARMA

by jbertholdin Biotech, Pharma

4P-PHARMA

About the company

4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases.

They aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI tech companies.

Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, their key differentiation is their dual leverage of in-house R&D capabilities located within the Pasteur Institute of Lille, combined with Single Product Vehicle (SPV)-based deployment in charge of advancing the assets through accelerated clinical development to market approvals and distribution agreements by geographic and therapeutic area.

About the solution

Since 2014, the team has reviewed more than 400 projects from different sources of innovation, more then 30 entered in their laboratories for a technical due diligence and 2 have been selected for clinical development.

Two SPVs have been launched:

–  4Living Biotech dedicated to the clinical development of 4P021, a first-in-class treatment for acute respiratory distress syndrome (ARDS) and pulmonary complications.

    –  4Moving Biotech dedicated to the clinical development of 4P004, a first-in-class disease modifying treatment for osteoarthritis.

    Website
    Key information

    –  Therapeutic areas: Chronic and autoimmune diseases, Respiratory and infectious diseases, Preventive therapies, Ophtalmological diseases

    –  Based in: Lille & Paris (FRANCE)

    –  Employees: 11 – 50

    –  Created in: 2014